Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
A variety of antibodies detect the antigen defined by the cluster designation group 15 (CD15). These antibodies have been reported to be helpful in the diagnosis of many different diseases, including leukemia. Hodgkin's disease, non-Hodgkin's lymphoma, and many carcinomas. We compared the expression of monoclonal antibody CD15 (C3D-1) in a group of thyroid neoplasms to determine whether there were differences in the expression of CD15 in various tumor types. Twenty samples representing normal thyroid tissues. 15 Graves' disease. 17 Hashimoto's disease, 15 adenomatous goiter, 30 follicular adenoma, 25 follicular carcinoma, 72 papillary carcinoma, 10 medullary carcinoma, and 18 undifferentiated carcinoma were analyzed by immunohistochemistry. Sixty-one (84.7%) of 72 cases of papillary carcinoma were positive for CD15 immunostaining. The other lesions were CD15-negative except for 1 (4.0%) of the 25 follicular carcinomas and 2 (20.0%) of the 10 medullary carcinomas. Our results indicate that CD15 may be used as a marker for papillary carcinoma of the thyroid gland.
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Jan 1, 1998
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.